PT2175875T - Composições de fenilalanina amoníaco/liase procariótica e métodos de tratamento de cancro utilizando as suas composições - Google Patents

Composições de fenilalanina amoníaco/liase procariótica e métodos de tratamento de cancro utilizando as suas composições

Info

Publication number
PT2175875T
PT2175875T PT87953576T PT08795357T PT2175875T PT 2175875 T PT2175875 T PT 2175875T PT 87953576 T PT87953576 T PT 87953576T PT 08795357 T PT08795357 T PT 08795357T PT 2175875 T PT2175875 T PT 2175875T
Authority
PT
Portugal
Prior art keywords
compositions
lyase
methods
treating cancer
phenylalanine ammonia
Prior art date
Application number
PT87953576T
Other languages
English (en)
Portuguese (pt)
Inventor
D Kakkis Emil
A Fitzpatrick Paul
C Vellard Michel
J Wendt Daniel
Muthalif Mubarack
m bell Sean
O Okhamafe Augustus
Original Assignee
Biomarin Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40363135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2175875(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biomarin Pharm Inc filed Critical Biomarin Pharm Inc
Publication of PT2175875T publication Critical patent/PT2175875T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51Lyases (4)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT87953576T 2007-08-17 2008-08-15 Composições de fenilalanina amoníaco/liase procariótica e métodos de tratamento de cancro utilizando as suas composições PT2175875T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US6612507P 2007-08-17 2007-08-17

Publications (1)

Publication Number Publication Date
PT2175875T true PT2175875T (pt) 2016-11-21

Family

ID=40363135

Family Applications (1)

Application Number Title Priority Date Filing Date
PT87953576T PT2175875T (pt) 2007-08-17 2008-08-15 Composições de fenilalanina amoníaco/liase procariótica e métodos de tratamento de cancro utilizando as suas composições

Country Status (23)

Country Link
US (4) US7537923B2 (cg-RX-API-DMAC7.html)
EP (1) EP2175875B1 (cg-RX-API-DMAC7.html)
JP (1) JP5584120B2 (cg-RX-API-DMAC7.html)
CN (1) CN101803492B (cg-RX-API-DMAC7.html)
AR (2) AR067972A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008289549B2 (cg-RX-API-DMAC7.html)
BR (2) BRPI0811589B8 (cg-RX-API-DMAC7.html)
CA (1) CA2687028C (cg-RX-API-DMAC7.html)
CL (1) CL2008002390A1 (cg-RX-API-DMAC7.html)
CY (1) CY1118222T1 (cg-RX-API-DMAC7.html)
DK (1) DK2175875T3 (cg-RX-API-DMAC7.html)
ES (1) ES2602618T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20161474T1 (cg-RX-API-DMAC7.html)
HU (1) HUE029510T4 (cg-RX-API-DMAC7.html)
LT (1) LT2175875T (cg-RX-API-DMAC7.html)
MX (1) MX2009012261A (cg-RX-API-DMAC7.html)
PE (1) PE20090605A1 (cg-RX-API-DMAC7.html)
PL (1) PL2175875T3 (cg-RX-API-DMAC7.html)
PT (1) PT2175875T (cg-RX-API-DMAC7.html)
RU (2) RU2553343C2 (cg-RX-API-DMAC7.html)
SI (1) SI2175875T1 (cg-RX-API-DMAC7.html)
TW (1) TWI418787B (cg-RX-API-DMAC7.html)
WO (1) WO2009025760A2 (cg-RX-API-DMAC7.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7537923B2 (en) * 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
WO2009064838A1 (en) * 2007-11-15 2009-05-22 Amgen, Inc. Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
US20110201022A1 (en) * 2008-07-30 2011-08-18 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase
WO2011078667A2 (en) 2009-12-22 2011-06-30 Dsm Ip Assets B.V. Method of finding a biocatalyst having ammonia lyase activity
DK3025728T3 (en) 2010-02-04 2018-10-29 Biomarin Pharm Inc PROCEDURE FOR PURIFICATION OF PROKARYOTIC PHENYLALANINE AMMONIAK LYASE VARIATIONS
US20120148559A1 (en) 2010-12-01 2012-06-14 Board Of Regents The University Of Texas System Compositions and method for deimmunization of proteins
US20150246083A1 (en) * 2012-07-27 2015-09-03 University Of North Texas Genetically modified probiotic for the treatment of phenylketonuria (pku) disease
KR102218930B1 (ko) 2013-04-18 2021-02-23 코덱시스, 인코포레이티드 조작된 페닐알라닌 암모니아 리아제 폴리펩티드
AU2014348683B2 (en) 2013-11-18 2020-11-05 Rubius Therapeutics, Inc. Synthetic membrane-receiver complexes
MX2020000621A (es) 2014-04-01 2020-11-12 Rubius Therapeutics Inc Composiciones para usarse en inmunomodulacion.
CA2943432A1 (en) 2014-04-16 2015-10-22 Codexis, Inc. Engineered tyrosine ammonia lyase
GB2535937B (en) 2014-04-29 2017-05-31 Bio-Cancer Treat Int Ltd Arginase I for treating rheumatoid arthritis
EP3169791A1 (en) 2014-07-14 2017-05-24 Danmarks Tekniske Universitet Processes for the production of hydroxycinnamic acids using polypeptides having tyrosine ammonia lyase activity
KR102702200B1 (ko) 2014-12-22 2024-09-02 코덱시스, 인코포레이티드 인간 알파-갈락토시다제 변이체
KR20230161535A (ko) 2016-07-26 2023-11-27 바이오마린 파머수티컬 인크. 신규 아데노-관련 바이러스 캡시드 단백질
IT201600086488A1 (it) * 2016-08-22 2018-02-22 St Microelectronics Srl Dispositivo a semiconduttore e corrispondente procedimento
WO2018148633A1 (en) * 2017-02-13 2018-08-16 Codexis, Inc. Engineered phenylalanine ammonia lyase polypeptides
MX2020011937A (es) 2018-05-09 2021-01-29 Biomarin Pharm Inc Metodos de tratamiento de fenilcetonuria.
TW202005978A (zh) 2018-05-14 2020-02-01 美商拜奧馬林製藥公司 新穎肝靶向腺相關病毒載體
US10900055B2 (en) 2018-06-12 2021-01-26 Codexis, Inc. Engineered tyrosine ammonia lyase
WO2020123286A1 (en) 2018-12-14 2020-06-18 Codexis, Inc. Engineered tyrosine ammonia lyase
CN113544268A (zh) 2018-12-20 2021-10-22 科德克希思公司 人类α半乳糖苷酶变体
IL285265B2 (en) 2019-02-14 2024-12-01 Som Innovation Biotech S A Triamterene or nolatrexed for use in the treatment of phenylketonuria
JP2022543611A (ja) * 2019-08-07 2022-10-13 ラクテン・メディカル,インコーポレイテッド セツキシマブ-ir700コンジュゲート組成物
KR20220106738A (ko) 2019-08-30 2022-07-29 코덱시스, 인코포레이티드 조작된 리파제 변이체
JP2023507575A (ja) 2019-12-20 2023-02-24 コデクシス, インコーポレイテッド 操作された酸性アルファ-グルコシダーゼバリアント
KR20220137057A (ko) 2020-02-04 2022-10-11 코덱시스, 인코포레이티드 조작된 류신 데카르복실라제
TW202144575A (zh) 2020-04-03 2021-12-01 美商拜奧馬林製藥公司 使用aav及治療調配物之苯酮尿症治療
BR112023003643A2 (pt) 2020-08-28 2023-03-28 Codexis Inc Amilase recombinante, composição, sequência de polinucleotídeo recombinante, vetor de expressão, célula hospedeira, métodos para produzir uma amilase recombinante e para tratar e/ou prevenir os sintomas de insuficiência pancreática, composição farmacêutica para o tratamento de insuficiência pancreática, e, uso
CA3191867A1 (en) 2020-08-28 2022-03-03 Codexis, Inc. Engineered protease variants
EP4341394A4 (en) 2021-05-19 2025-04-09 BioMarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia lyase and methods for treating adolescent patients
EP4341395A4 (en) 2021-05-21 2025-07-23 Syntis Bio Inc MODIFIED METHIONINE GAMMA LYASE VARIANTS
AU2022377148A1 (en) 2021-11-01 2024-06-13 Syntis Bio, Inc. Engineered leucine decarboxylases
CN115873837A (zh) * 2022-11-18 2023-03-31 安徽盈科生物科技有限公司 高表达的新型的苯丙氨酸解氨酶
CN118931888A (zh) * 2023-05-09 2024-11-12 重庆派金生物科技有限公司 苯丙氨酸裂解酶突变体及其偶联物或其药学上可接受的盐
GB202307239D0 (en) 2023-05-15 2023-06-28 Evox Therapeutics Ltd Gene therapies for Phenylketonuria
US20250161466A1 (en) 2023-11-17 2025-05-22 Biomarin Pharmaceutical Inc. Conjugates of phenylalanine ammonia-lyase and poegma and methods for their use

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4252822A (en) * 1979-12-26 1981-02-24 Children's Hospital Medical Center Method for treating phenylketonuria
US4562151A (en) * 1983-09-06 1985-12-31 Monsanto Company Stabilization of L-phenylalanine ammonia-lyase enzyme
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5766897A (en) * 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5212939A (en) * 1991-12-04 1993-05-25 Pratt Jr John M Marine mooring swivel fitting
DE69334292D1 (de) * 1992-11-19 2009-10-08 Anticancer Inc Verwendung von Methioninase als Antitumormittel in der Antimethionin-chemotherapie
CA2149922C (en) 1992-12-04 2007-05-15 Thomas W. Macallister Genetically engineered glutaminase and its use in antiviral and anticancer therapy
DK75593D0 (cg-RX-API-DMAC7.html) * 1993-06-25 1993-06-25 Novo Nordisk As
KR0164757B1 (ko) * 1995-06-13 1999-01-15 김광호 공조장치의 살균집진장치와 그 방법
EP0851925B1 (en) * 1995-09-21 2005-08-03 Genentech, Inc. Human growth hormone variants
CU22585A1 (es) * 1995-11-17 1999-11-03 Centro Inmunologia Molecular Anticuerpos monoclonales antiidiótipos (ab2) de tipo igg con alta conectividad idiotípica y composiciones farmacéuticas que los contienen. su uso como inmunoreguladores de la respuesta inmune.
US6548644B1 (en) * 1997-03-10 2003-04-15 Immunex Corporation Site protected protein modification
US6183738B1 (en) * 1997-05-12 2001-02-06 Phoenix Pharamacologics, Inc. Modified arginine deiminase
US5981239A (en) * 1997-09-24 1999-11-09 Great Lakes Chemical Corp. Synthesis of optically active phenylalanine analogs using Rhodotorula graminis
US6451986B1 (en) * 1998-06-22 2002-09-17 Immunex Corporation Site specific protein modification
US6461849B1 (en) 1998-10-13 2002-10-08 Novozymes, A/S Modified polypeptide
US6686164B1 (en) 1998-10-30 2004-02-03 Novozymes A/S Low allergenic protein variants
IL138990A0 (en) 1999-02-12 2001-11-25 Biostream Inc Matrices for drug delivery and methods for making and using the same
US6586398B1 (en) * 2000-04-07 2003-07-01 Amgen, Inc. Chemically modified novel erythropoietin stimulating protein compositions and methods
AU2001257032A1 (en) * 2000-04-14 2001-10-30 University Of South Carolina Research Foundation Cloning, overexpression and therapeutic uses of bioactive histidine ammonia lyase
US6967097B2 (en) * 2000-07-24 2005-11-22 Pcbu Services, Inc. Phenylalainine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same
US6939941B2 (en) * 2001-09-12 2005-09-06 Toray Fine Chemicals Co., Ltd. Preparation of polysulfide compositions
DE60323607D1 (de) 2002-02-26 2008-10-30 Du Pont Verfahren zur rekombination genetischer elemente
CA2506026A1 (en) 2002-11-14 2004-05-27 The Scripps Research Institute Crystalline form of fatty acid amine hydrolase (faah)
CA2580679A1 (en) 2004-09-17 2006-03-30 Biomarin Pharmaceutical Inc. Variants and chemically-modified variants of phenylalanine ammonia-lyase
CA2614769A1 (en) * 2005-03-10 2006-09-21 Verenium Corporation Lyase enzymes, nucleic acids encoding them and methods for making and using them
US7531341B1 (en) 2006-06-12 2009-05-12 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US7534595B2 (en) 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
DE102006032167B4 (de) 2006-07-12 2014-11-27 Evonik Degussa Gmbh Verfahren zur Herstellung von Triallylisocyanurat (TAIC)
WO2008069958A2 (en) 2006-12-01 2008-06-12 The Salk Institute For Biological Studies Substrate switched ammonia lyases and mutases
US7537923B2 (en) 2007-08-17 2009-05-26 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof
US20110201022A1 (en) 2008-07-30 2011-08-18 Biomarin Pharmaceutical Inc. Assays for detection of phenylalanine ammonia-lyase and antibodies to phenylalanine ammonia-lyase

Also Published As

Publication number Publication date
WO2009025760A2 (en) 2009-02-26
RU2012134838A (ru) 2014-03-20
BRPI0811589B1 (pt) 2020-05-12
AU2008289549A1 (en) 2009-02-26
US7537923B2 (en) 2009-05-26
SI2175875T1 (sl) 2017-01-31
CA2687028A1 (en) 2009-02-26
RU2009141987A (ru) 2011-05-20
EP2175875A2 (en) 2010-04-21
CL2008002390A1 (es) 2009-05-29
CY1118222T1 (el) 2017-06-28
BRPI0811589A2 (pt) 2014-10-29
US7560263B2 (en) 2009-07-14
HUE029510T4 (en) 2017-05-29
US7790433B2 (en) 2010-09-07
BR122018072594B8 (pt) 2021-07-27
CN101803492B (zh) 2014-05-07
PL2175875T3 (pl) 2017-04-28
CN101803492A (zh) 2010-08-11
HRP20161474T1 (hr) 2016-12-30
TW200911283A (en) 2009-03-16
HUE029510T2 (hu) 2017-02-28
US20090263369A1 (en) 2009-10-22
LT2175875T (lt) 2016-12-12
EP2175875B1 (en) 2016-10-05
DK2175875T3 (en) 2016-11-21
AR067972A1 (es) 2009-10-28
ES2602618T3 (es) 2017-02-21
JP2010536759A (ja) 2010-12-02
US20090047268A1 (en) 2009-02-19
WO2009025760A3 (en) 2009-06-25
BRPI0811589B8 (pt) 2021-05-25
JP5584120B2 (ja) 2014-09-03
BR122018072594B1 (pt) 2020-10-27
RU2553343C2 (ru) 2015-06-10
MX2009012261A (es) 2010-03-15
CA2687028C (en) 2016-02-16
AU2008289549B2 (en) 2014-02-06
AR117389A2 (es) 2021-08-04
US20090047265A1 (en) 2009-02-19
PE20090605A1 (es) 2009-05-16
US20100278802A1 (en) 2010-11-04
TWI418787B (zh) 2013-12-11

Similar Documents

Publication Publication Date Title
LT2175875T (lt) Prokariotinės fenilanino liazės kompozicijos ir jų panaudojimas vėžio gydymo būduose
HUS1900049I1 (hu) Prokarióta fenilalanin ammónia-liáz készítmények és azok alkalmazási eljárásai
IL257681A (en) Methods and compositions for the treatment of cancer
PL2155188T3 (pl) Sposoby i kompozycje do leczenia nawrotowego raka
SI2200431T1 (sl) Sestave in metode za zdravljenje raka
IL257437B (en) Compositions of prokaryotic phenylalanine ammonia lyase variants and methods of using the compositions
PL2340042T3 (pl) Sposoby i kompozycje do leczenia raka
PT2977456T (pt) Composições compreendendo hmw-maa e seus fragmentos para tratamento do cancro
EP2049151A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
ZA201006988B (en) Method and compositions for treatment of cancer
EP2176406A4 (en) COMPOSITIONS AND METHOD FOR CANCER TREATMENT
IL243294A0 (en) Compounds and compositions for the treatment of cancer
SI2187967T1 (sl) Postopki in sestavki za zdravljenje raka
IL204945A0 (en) Compositions and methods for inhibiting tumor progression
EP2137213A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF PROSTATE CANCER
EP1996211A4 (en) GALLIUM COMPOSITIONS FOR THE TREATMENT OF LIVER CANCER AND METHODS OF USE
EP1855662A4 (en) METHODS AND COMPOSITIONS FOR TREATING CANCER
EP2068629A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANCER
PT3067054T (pt) Novas composições e métodos para o tratamento de cancro
SI3067054T1 (sl) Novi sestavki in postopki za zdravljenje raka
GB2454875B (en) Parenteral composition for use in treatment of cancer and method of manufacture thereof
AU2007904940A0 (en) Methods and compositions for treating gynecological cancer
IL196361A0 (en) Combination methods of treating cancer
AU2007901628A0 (en) Methods and compositions for treating prostate cancer
HK1122507A (en) Methods and compositions for treating prostate cancer